<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364894</url>
  </required_header>
  <id_info>
    <org_study_id>NL59694.091.17</org_study_id>
    <nct_id>NCT03364894</nct_id>
  </id_info>
  <brief_title>The Personalized Parkinson Project (PPP)</brief_title>
  <acronym>PPP</acronym>
  <official_title>The Personalized Parkinson Project (De Parkinson Op Maat Studie)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verily Life Sciences LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ParkinsonNet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parkinson Vereniging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Topsector Life Sciences and Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Nijmegen (City Hall)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Province of Gelderland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Our understanding of PD has stagnated, partly due to the limited patient diversity
      and brief followup captured in most study cohorts. Additionally, potentially valuable
      biomarkers derived from different types of measurements are rarely analyzed in an integrated
      fashion.

      Objective This study aims to create a longitudinal dataset of clinical, molecular, imaging,
      and continuous wearable sensor-based data from a representative Parkinson's disease (PD)
      cohort. Data will be made available to researchers worldwide to accelerate the discovery of
      novel etiological insights, development of new therapeutic approaches, and personalized
      disease management. For this purpose, an extensible norm for sharing research data will be
      developed, meeting the latest data privacy and security standards.

      Methods Supported by a multinational, public-private partnership, a prospective cohort study
      was designed to include 650 representative PD patients (disease duration &lt;5 years).
      Comprehensive follow-up for at least 2 years includes: (1) annual assessment at the study
      center for acquisition of detailed clinimetric data, magnetic resonance imaging, and
      biospecimens (plasma, serum, cerebrospinal fluid (CSF), stool) and (2) collection of data
      from the home environment, using self-assessments and an advanced wrist-worn wearable device
      to continuously measure biological and environmental signals. Collection, storage, and
      sharing of these research data will be facilitated by a new method to protect privacy and
      enhance security using polymorphic encryption and pseudonymization (PEP), a methodology that
      combines advanced encryption with distributed pseudonymization and data access management.

      Conclusion This study is unique, as it includes a cohort of unbiased subjects with recently
      diagnosed PD, creating an unprecedented dataset that combines longitudinally collected
      clinical, molecular, imaging, and data from wearable sensors using state of the art
      technology. The single-center study design minimizes measurement variability. Finally, the
      innovative methodology for data privacy and protection might serve as a new international
      standard for sharing research data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Personalized Parkinson Project proposes an unbiased approach to biomarker development
      with multiple clinical, genomic and other molecular, and imaging biomarkers measured in a
      large population, measured at 3 time points (baseline visit, one year follow-up, and two
      years' follow-up). In addition, the study protocol includes day-to-day patient monitoring
      with a multisensor wearable device, the Verily Study Watch, that continuously collects data
      (movement, pulse, skin temperature, ambient information) and allows for real-time data
      collection between study visits. The goal of the device is to collect high-resolution,
      continuous biological signals from the body. These measurements of physiology, activity, and
      environmental conditions over the course of a 2-year study will be used to create a
      quantified functional assessment of patients with PD. Mapping these signals with clinical
      outcomes such as disease progression will allow the investigators to evaluate the
      relationship between biosensor data and the clinical variables, genotypic, and imaging
      biomarkers collected in the study.

      This study is intended to create a unique resource of genotypic, functional, and phenotypic
      data collected longitudinally on a cohort of Dutch subjects with PD (n=650), allowing the
      Research Collaborators to address a series of hypothesis-driven research questions. The aim
      is to develop novel etiological insights, to identify biomarkers that can assist in
      predicting differences in prognosis and treatment response between patients, to improve
      existing treatments, to develop new therapeutic approaches, and to develop a more precise and
      personalized disease management approach.

      Additionally, the cohort will serve as a source of data that can be accessed by qualified
      researchers worldwide, allowing them to add their research capacity to further address the
      main aims of this study. For this reason, data governance will be managed by dedicated
      advisory boards and data review committees, as specified in the study protocol. Participation
      in this study and results from this study will not be used for patient treatment decisions.

      The aim of this study is threefold:

        1. The primary objective of the study is to perform a set of hypothesis-driven analyses on
           the study data set, aiming to correlate established biomarkers (obtained clinically,
           from brain magnetic resonance imaging (MRI), from cerebrospinal fluid (CSF), from known
           genetic factors, and from monitoring of biosensors signals) to the rate of disease
           progression, and to responses to treatment (both pharmacological and behavioral, such as
           participation in exercise). Also, the investigators aim to identify biomarkers that can
           assist in predicting differences in prognosis and treatment response between patients.
           Finally, by developing novel etiological and pathophysiological insights, the study aims
           to improve existing treatments and to develop new therapeutic approaches, as a basis for
           development of a more precise and personalized disease management approach.

        2. The secondary objective of the study is to evaluate the Verily Study Watch, to assess
           how these devices could provide information about the function of patients with PD.

        3. The tertiary objective of this study is to create an extensive longitudinal dataset
           describing the genetic, clinical, functional, and phenotypic characteristics of a
           representative Parkinson's disease (PD) subject cohort (n = 650) to allow researchers to
           investigate important unanswered questions in PD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term disease progression in terms of motor symptoms</measure>
    <time_frame>From baseline till 1 year follow-up</time_frame>
    <description>Change in Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score, measured in off state. This scale assesses 18 motor symptoms (33 items) that are specific for Parkinson's disease. Item scores range from 0 to 4 and are summed, resulting in a total score ranging from 0 to 132, with higher scores representing worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term disease progression in terms of cognitive functioning</measure>
    <time_frame>From baseline till 1 year follow-up</time_frame>
    <description>Change in Montreal Cognitive Assessment (MoCA) score. The MoCa assesses in 30 items different types of cognitive abilities (0-1 scale), including orientation, short-term memory and attention. All items are summed, resulting in a total score ranging from 0 to 30, with higher scores representing better outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mid-term disease progression in terms of motor symptoms</measure>
    <time_frame>From baseline till 2 year follow-up</time_frame>
    <description>Change in MDS-UPDRS part III score, measured in off state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mid-term disease progression in terms of cognitive functioning</measure>
    <time_frame>From baseline till 2 year follow-up</time_frame>
    <description>Change in Montreal Cognitive Assessment (MoCA) score</description>
  </primary_outcome>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Parkinson Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood specimen and stool collection from all enrolled patients and cerebrospinal fluid (CSF)
      from patients who have provided additional and optional consent to CSF collection, for
      longitudinal genotypic and phenotypic assays.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any person with Parkinson's disease who meets the inclusion criteria and does not meet the
        exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has Parkinson's disease of â‰¤5 years duration, defined as time since diagnosis
             made by a neurologist.

          -  Subject is an adult, at least 18 years of age.

          -  Subject can read and understand Dutch.

          -  Subject has completed the Informed Consent form, as approved by the Ethics Committee.

          -  Subject is willing, competent, and able to comply with all aspects of the protocol,
             including follow-up schedule and biospecimen collection.

          -  Subject is not a current employee or family member of employees of the institutions
             involved in the study.

        Exclusion Criteria:

          -  Subject is pregnant or breastfeeding.

          -  Subject is allergic to nickel.

          -  Subject has co-morbidities that would hamper interpretation of parkinsonian
             disability, such as coincident musculoskeletal abnormalities, in the opinion of the
             Investigator.

          -  Contraindicated for MRI, e.g. claustrophobia, presence of an active implant,
             pacemaker, insulin pump, neurostimulator, ossicle prosthesis, and/or other medical
             device or other non-removable metal part incompatible with MRI.

          -  For lumbar puncture:

               -  Allergy to local anesthetic agents

               -  Medical history of compression of spinal cord, current local skin infection at
                  the site of the lumbar puncture, developmental abnormalities in lower spine,
                  blood coagulopathy, anticoagulant medication (Acenocoumarol, Warfarin,
                  Dabigatran).

               -  Clinical (or previous MRI) evidence of structural cerebral abnormalities that are
                  not compatible with the performance of a lumbar puncture such as malignancies,
                  abscess, or obstructive hydrocephalus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bastiaan R Bloem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud university medical center, department of neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marjan Faber, PhD</last_name>
    <phone>+31243613450</phone>
    <email>marjan.faber@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tessa van de Zande, MSc</last_name>
    <phone>+31243613450</phone>
    <email>tessa.vandezande@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Faber, PhD</last_name>
      <phone>+31 243613450</phone>
      <email>info@parkinsonopmaat.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.parkinsonopmaat.nl/studie</url>
    <description>Personalized Parkinson Project study webpage</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Wearable sensors</keyword>
  <keyword>Imaging</keyword>
  <keyword>Disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The dataset generated in this study will become available to qualified researchers worldwide, provided research questions are approved by the Research and Data Sharing Review Committee (RDSRC). The RDSRC will protect subjects' privacy by limiting the availability of the study data and controlling access to sources of information that might potentially be used to identify the individual subjects associated with the biospecimen analysis.
The RDSRC will assess the relevance and scientific quality of research proposals for which study data or material is requested. These responsibilities include the consideration of applications for:
access to the resources obtained in this study, including data or biomaterials
applications for endorsement of a scientific project using study materials;
applications for endorsement of a clinical study using study materials.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

